Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study.

Autor: Armengou-Garcia L; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain., Sanchez-Catasus CA; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Aviles-Olmos I; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Neuroscience, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Jiménez-Huete A; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain., Montoya-Murillo G; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain., Gorospe A; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain., Martin-Bastida A; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain., Gonzalez-Quarante LH; Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain., Guridi J; Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain., Rodriguez-Oroz MC; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Neuroscience, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18.
DOI: 10.1002/mds.30020
Abstrakt: Background: Unilateral subthalamic nucleus (STN) ablation using magnetic resonance-guided focused ultrasound (MRgFUS) is being explored as a new treatment for asymmetric Parkinson's disease (PD).
Objectives: The aims were to study the efficacy and safety of this treatment in asymmetric PD patients and to characterize the lesions.
Methods: This prospective, single-center, open-label study evaluated asymmetric PD patients at 6 (n = 20) and 12 months (n = 12) after MRgFUS lesion of the STN. The primary outcome was the change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS III), score in off medication on the treated side and the adverse events (AEs) at 6-month follow-up. We also evaluated cognitive-neuropsychological changes, self-assessment of clinical improvement, and the correlation of the lesion volume with the motor outcomes.
Results: On the treated side, the MDS-UPDRS III score (mean difference = 13.8) and the scores in rigidity, bradykinesia, and tremor improved (P < 0.001) throughout the follow-up compared to baseline (at 6 months: rigidity mean difference = 2.8, improvement: 83.5%; bradykinesia mean difference = 6.0, improvement: 69.4%; tremor mean difference = 4.7, improvement: 91.5%). One patient had severe weakness in the treated hemibody, 1 had moderate dyskinesia, and 1 was in moderate confusional state that became mild (weakness) or completely resolved (dyskinesia and confusional state) at 6 months. The rest of the AEs were mild. We observed no clinically relevant changes in cognitive-neuropsychological tests. The percentage of ablation of the STN correlated with the improvement in the total MDS-UPDRS III and contralateral tremor scores (P < 0.05).
Conclusion: Unilateral MRgFUS lesion of the STN resulted in a significant motor improvement. We observed no persistent severe AEs, although mild, mostly transient AEs were frequent. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
(© 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz: